• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硼替佐米诱导的肺毒性：一例病例报告及文献综述

Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.

作者信息

Kharel Prakash, Uprety Deekchha, Chandra Abhinav B, Hu Yirui, Belur Anuradha Avinash, Dhakal Ajay

机构信息

Department of Hospital Medicine, Geisinger Medical Center, 100 N Academy Ave., Danville, PA 17821, USA.

Renal Division, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Case Rep Med. 2018 Nov 25;2018:2913124. doi: 10.1155/2018/2913124. eCollection 2018.

DOI:10.1155/2018/2913124
PMID:30595697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6286773/
Abstract

Bortezomib, a proteasome inhibitor, is an established therapy against multiple myeloma. Bortezomib-induced lung injury, although not appreciated during the introductory time of the medication, has now been highlighted in multiple case reports. The objective of this study is to report a case of bortezomib-induced lung injury, review current literature, and perform exploratory analysis.

摘要

硼替佐米，一种蛋白酶体抑制剂，是一种已被认可的治疗多发性骨髓瘤的药物。硼替佐米引起的肺损伤，尽管在该药物引入初期未被重视，但现在已在多篇病例报告中被强调。本研究的目的是报告一例硼替佐米引起的肺损伤病例，回顾当前文献，并进行探索性分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/a5ca960b092e/CRIM2018-2913124.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/169016172fd6/CRIM2018-2913124.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/29abe79e66fd/CRIM2018-2913124.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/a5ca960b092e/CRIM2018-2913124.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/169016172fd6/CRIM2018-2913124.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/29abe79e66fd/CRIM2018-2913124.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ff/6286773/a5ca960b092e/CRIM2018-2913124.003.jpg

相似文献

1
Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.硼替佐米诱导的肺毒性：一例病例报告及文献综述
Case Rep Med. 2018 Nov 25;2018:2913124. doi: 10.1155/2018/2913124. eCollection 2018.
2
Bortezomib induced pulmonary toxicity: a case report and review of the literature.硼替佐米诱导的肺毒性：一例病例报告及文献综述
Am J Blood Res. 2020 Dec 15;10(6):407-415. eCollection 2020.
3
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.硼替佐米诱发的多发性骨髓瘤严重肺部并发症：一例报告及文献综述
Oncol Lett. 2016 Mar;11(3):2255-2260. doi: 10.3892/ol.2016.4204. Epub 2016 Feb 8.
4
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).使用HIV蛋白酶抑制剂奈非那韦进行治疗可引发未折叠蛋白反应，并且与硼替佐米联合使用时可能克服多发性骨髓瘤对蛋白酶体抑制剂的耐药性：一项I期试验（SAKK 65/08）。
Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.
5
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.日本复发/难治性多发性骨髓瘤中硼替佐米治疗相关的肺损伤：来自日本血液学会和日本临床血液学会“硼替佐米所致肺损伤”联合委员会的一份基于问卷调查的报告
Int J Hematol. 2006 Dec;84(5):406-12. doi: 10.1532/IJH97.06142.
6
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].[日本复发/难治性多发性骨髓瘤中硼替佐米治疗相关的肺损伤：日本血液学会和日本临床血液学会“硼替佐米所致肺损伤”联合委员会基于问卷调查的报告]
Rinsho Ketsueki. 2006 Dec;47(12):1521-7.
7
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.硼替佐米治疗难治性多发性骨髓瘤后日本患者出现的严重肺部并发症。
Blood. 2006 May 1;107(9):3492-4. doi: 10.1182/blood-2005-11-4541. Epub 2006 Jan 12.
8
Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.硼替佐米治疗多发性骨髓瘤患者后急性肺动脉高压的发生：1例病例报告及文献复习
Am J Ther. 2015 May-Jun;22(3):e88-92. doi: 10.1097/01.mjt.0000433941.91996.5f.
9
The safety of bortezomib for the treatment of multiple myeloma.硼替佐米治疗多发性骨髓瘤的安全性。
Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30.
10
Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.硼替佐米单药治疗难治性多发性骨髓瘤患者的长期疾病控制：一例病例报告及文献综述
Int J Clin Exp Med. 2015 Oct 15;8(10):19629-31. eCollection 2015.

引用本文的文献

1
Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.用于癌症治疗的泛素特异性蛋白酶抑制剂：最新进展与未来展望
Biomolecules. 2025 Feb 7;15(2):240. doi: 10.3390/biom15020240.
2
Bortezomib Increased Vascular Permeability by Decreasing Cell-Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells.硼替佐米通过降低人肺微血管内皮细胞细胞间连接分子增加血管通透性。
Int J Mol Sci. 2023 Jun 29;24(13):10842. doi: 10.3390/ijms241310842.
3
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.

本文引用的文献

1
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.卡非佐米或硼替佐米治疗复发或难治性多发性骨髓瘤（ENDEAVOR）：一项开放标签、随机、3 期临床试验的中期总生存分析。
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
2
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.硼替佐米诱发的多发性骨髓瘤严重肺部并发症：一例报告及文献综述
Oncol Lett. 2016 Mar;11(3):2255-2260. doi: 10.3892/ol.2016.4204. Epub 2016 Feb 8.
3
Early-Onset Severe Diffuse Alveolar Hemorrhage after Bortezomib Administration Suggestive of Pulmonary Involvement of Myeloma Cells.
基因组筛查揭示泛素样修饰激活酶1是c-MYC高表达三阴性乳腺癌模型中的一个有效且可成药的靶点。
PNAS Nexus. 2022 Oct 11;1(5):pgac232. doi: 10.1093/pnasnexus/pgac232. eCollection 2022 Nov.
4
USP10 as a Potential Therapeutic Target in Human Cancers.USP10 作为人类癌症的潜在治疗靶点。
Genes (Basel). 2022 May 6;13(5):831. doi: 10.3390/genes13050831.
5
Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.泛素特异性蛋白酶（USP）抑制剂的研发进展
Int J Mol Sci. 2021 Apr 27;22(9):4546. doi: 10.3390/ijms22094546.
6
Bortezomib induced pulmonary toxicity: a case report and review of the literature.硼替佐米诱导的肺毒性：一例病例报告及文献综述
Am J Blood Res. 2020 Dec 15;10(6):407-415. eCollection 2020.
7
Dienone Compounds: Targets and Pharmacological Responses.二烯酮化合物：作用靶点与药理反应
J Med Chem. 2020 Dec 24;63(24):15075-15093. doi: 10.1021/acs.jmedchem.0c00812. Epub 2020 Nov 4.
8
Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia.硼替佐米诱发浆细胞白血病患者弥漫性肺泡出血。
Respir Med Case Rep. 2020 Jul 21;31:101169. doi: 10.1016/j.rmcr.2020.101169. eCollection 2020.
9
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.通过去泛素化酶抑制剂 VLX1570 诱导急性淋巴细胞白血病细胞内质网应激。
Int J Mol Sci. 2020 Jul 4;21(13):4757. doi: 10.3390/ijms21134757.
10
Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome.蛋白酶体功能障碍在肺泡 II 型上皮细胞中与急性呼吸窘迫综合征有关。
Sci Rep. 2019 Aug 29;9(1):12509. doi: 10.1038/s41598-019-49020-4.
硼替佐米给药后出现的早期严重弥漫性肺泡出血提示骨髓瘤细胞累及肺部。
J Clin Exp Hematop. 2015;55(3):163-8. doi: 10.3960/jslrt.55.163.
4
Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).卡非佐米（凯普拉生™）所致的致命性肺毒性。
J Oncol Pharm Pract. 2016 Oct;22(5):720-4. doi: 10.1177/1078155215588630. Epub 2015 Jun 4.
5
Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma.
Ann Hematol. 2015 Aug;94(8):1425-6. doi: 10.1007/s00277-015-2392-1. Epub 2015 May 6.
6
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
7
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.卡非佐米治疗后心脏和血管事件的病例系列讨论：可能机制、筛查与监测
BMC Cancer. 2014 Dec 4;14:915. doi: 10.1186/1471-2407-14-915.
8
Bortezomib-induced lung toxicity.
Arch Bronconeumol. 2014 Dec;50(12):564-5. doi: 10.1016/j.arbres.2013.11.027. Epub 2014 Jan 17.
9
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.硼替佐米治疗相关肺部疾病在日本多发性骨髓瘤患者中的发病情况、死亡率和临床特征。
Cancer Sci. 2014 Feb;105(2):195-201. doi: 10.1111/cas.12335. Epub 2014 Jan 21.
10
Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.硼替佐米治疗多发性骨髓瘤患者后急性肺动脉高压的发生：1例病例报告及文献复习
Am J Ther. 2015 May-Jun;22(3):e88-92. doi: 10.1097/01.mjt.0000433941.91996.5f.